Share on LinkedInShare on LinkedIn

ARTICLE · 18 JULY 2022

When A Win May Not Really Be A Win

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Univ. of Mass v. L'Oréal USA, Inc., No. 21-1969 (Fed. Cir. June 13, 2022), the Court of Appeals for the Federal Circuit ("Federal Circuit") rejected the district court's claim constructions...

United StatesIntellectual Property

Holding

In Univ. of Mass v. L'Oréal USA, Inc., No. 21-1969 (Fed. Cir. June 13, 2022), the Court of Appeals for the Federal Circuit ("Federal Circuit") rejected the district court's claim constructions, vacated the indefiniteness ruling, and remanded the case for further proceedings.

Background

UMass sued L'Oréal for infringement of U.S. Pat. No. 6,423,327 ("the '327 patent") and 6,645,513 ("the '513 patent"). Representative claim 1 of the '327 patent read:

[a] method for enhancing the condition of unbroken skin of a mammal by reducing one or more of wrinkling, roughness, dryness, or laxity of the skin, without increasing dermal cell proliferation, the method comprising topically applying to the skin a composition comprising a concentration of adenosine in an amount effective to enhance the condition of the skin without increasing dermal cell proliferation, wherein the adenosine concentration applied to the dermal cells is 10-4M to 10-7M.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from